| Ytd | -3.41% | |
| 1y | -41.95% |
| Open | 1.19 | Prev Close | 1.19 | Low | 1.19 | High | 1.24 | Mkt Cap | 17.86M |
| Vol | 66.05K | Avg Vol | 3.09M | EPS | -0.85 | P/E | N/A | Forward P/E | -1.57 |
| Beta | 1.27 | Short Ratio | 1.41 | Inst. Own | 2.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 1.02 | 200-d Avg | 1.24 | 1yr Est | 25.00 |
BCDA News
Dear Fellow Shareholders,Upon completion of our recent capital raise, I am providing this update on
SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leade
BioCardia (BCDA) stock slides after a $4.4M share dilution, but analysts spot massive upside. Check
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy an
Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA
Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA
BioCardia Inc. (NASDAQ:BCDA) stock is up on Friday as the company is confirming progress toward pote
BioCardia stock breaks above its 200-day moving average on huge FDA news. Can BCDA clear the $1.50 r
BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the t
SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leade
Results presented by Dr. Raval, on behalf of the CardiAMP CMI Investigators, showed that the minimal
– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally deliver
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.21) per share which missed the analyst cons
SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of c
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the tr
SUNNYVALE, Calif. , May 08, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global lead
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the tr
NEW YORK--(BUSINESS WIRE)--Tamboran Resources Corporation (NYSE: TBN, ASX: TBN): Tamboran Resources
BioCardia (NASDAQ: BCDA) executives on Tuesday outlined new clinical data for the company's lead cel
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.06) per share which beat the analyst consen
SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leade
SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of
Shares of BioCardia, Inc. (NASDAQ: BCDA - Get Free Report) fell 3.9% on Wednesday. The company trade
BioCardia has had preliminary meetings with both FDA Center for Devices and Radiological Health (CDR
BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatme
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of
BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatm
SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of
SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.24) per share which beat the analyst consen
This prospectus supplement updates and amends certain information in our base prospectus, dated Dece
BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatme
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy an
